Ahmed Daak

Senior Clinical Research Director
Sanofi Genzyme
Bridgewater, New Jersey, United States

Presentation(s):

• OC 65.1 - Long-Term Efficacy and Safety With Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients With Immune Thrombocytopenia

  Tuesday, June 27, 2023
  14:45 – 15:00 ET